Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
Hauser RA, Videnovic A, Soares-da-Silva P, Liang GS, Olson K, Jen E, Rocha JF, Klepitskaya O. Hauser RA, et al. Among authors: liang gs. Parkinsonism Relat Disord. 2024 Apr 9;123:106971. doi: 10.1016/j.parkreldis.2024.106971. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 38631081 Free article.
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Among authors: liang gs. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P, Liang GS, Olanow CW, Kieburtz KD, Jimenez R, Olson K, Klepitskaya O, Loewen G. LeWitt P, et al. Among authors: liang gs. Clin Neuropharmacol. 2023 Mar-Apr 01;46(2):43-50. doi: 10.1097/WNF.0000000000000538. Epub 2023 Jan 21. Clin Neuropharmacol. 2023. PMID: 36688497 Free PMC article. Clinical Trial.
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, Li C, Liang GS, Meier A, Roberts EW, Pfau ML, Rodman JR, Bankiewicz KS, Larson PS. Christine CW, et al. Among authors: liang gs. Neurology. 2022 Jan 4;98(1):e40-e50. doi: 10.1212/WNL.0000000000012952. Epub 2021 Oct 14. Neurology. 2022. PMID: 34649873 Free PMC article.
A long-term, open-label study of valbenazine for tardive dyskinesia.
Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF. Lindenmayer JP, et al. Among authors: liang gs. CNS Spectr. 2021 Aug;26(4):345-353. doi: 10.1017/S109285292000108X. Epub 2020 May 18. CNS Spectr. 2021. PMID: 32419679
39 results